BMS doubles up with pivotal wins in lung disease, solid tumor that offer hope for post-patent cliff growth
8 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
Velocity
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
The brief
"BMS doubles up with pivotal wins in lung disease, solid tumor that offer hope for post-patent cliff growth" is generating significant coverage in the Business category, with 8 articles from 8 distinct sources tracked by PULSE so far.
Outlets currently covering the story include FirstWord Pharma, BioPharma Dive, BioSpace and Investor's Business Daily. PULSE measures a story's velocity from how quickly new articles appear and how many independent newsrooms join the coverage.
This brief was generated by PULSE's extractive engine from coverage metadata only. The latest headlines from every source are listed below; the velocity chart shows how the story is developing in real time.
Generated by PULSE's extractive engine from coverage metadata only — no AI-written claims. Updated 32d ago.
Quick answers
Why is "BMS doubles up with pivotal wins in lung disease, solid tumor that offer hope fo" trending?
Because 8 independent news sources published 8 articles about it in a short window — a coverage burst PULSE classifies as a trend.
How does PULSE measure this trend?
PULSE scores velocity from the rate of new articles weighted by source diversity, snapshotted hourly. The full method is public on our methodology page.
Is this trend still active?
The status badge on this page updates hourly: rising, peaking, cooling, or archived once coverage stops for 48 hours.
Coverage (8)
- BMS scores pivotal trial win for lower dose of admilparant in IPF FirstWord Pharma · 35d ago
- Bristol Myers dips on ‘confounding’ lung drug results BioPharma Dive · 35d ago
- BMS’ Phase 3 win for lung drug clouded by high-dose miss BioSpace · 35d ago
- Bristol Myers Reverses Lower Despite Double Phase 3 Win, As A Key Rival Crashes Investor's Business Daily · 35d ago
- Bristol Myers’ Drugs Succeed in Treating Lung Disease, Cancer Bloomberg.com · 35d ago
- Contineum Therapeutics Shares Surge 27% After Bristol Myers Squibb Reports Positive Phase 3 Trial Results Yahoo Finance · 35d ago
- Bristol Myers' lung disease drug succeeds at lower dose in late-stage trial Reuters · 35d ago
- BMS doubles up with pivotal wins in lung disease, solid tumor that offer hope for post-patent cliff growth Fierce Biotech · 35d ago
Topics
Related trends
BMS reunites R&D divisions under Cristian Massacesi, while Robert Plenge departs
Bristol Myers Squibb is restructuring its research and development organization under Cristian Massacesi as chief research officer Robert Plenge prepares to exit.